PTO/SB/08A (08/03) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitu	ite for	form 1449A/PTO		Applicati	ion Number	TBA 10 580 24 X			
INFORMATION DISCLOSURE				Internati	onal Filing Date	November 19, 2004			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					ned Inventor	Mimi ADACHI, et al.			
317			ANI	Art Unit	•	TBA			
		(use as many sheets as necessary)		Examine	r Name	Unassigned			
Sheet		1 of 4		Attorney Docket Number		64517.000003			
		7	IS PATI	ENT DO	CUMENTS				
	1			DIVI DO			Pages, Columns, Lines, Where		
*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	1	tion Date D-YYYY	Name of Paten Applicant of Cited		Relevant Passages or Relevant Figures Appear		
	1.	US- 2005/0208659 A1	09-22	2-2005	Ikeda, et	al.			
		US-							
		US-							
		US-				, , , , , , , , , , , , , , , , , , , ,			
		US-							
		US-		•					
		US-							
		US-							
		US-							
		US-							
		US-							
		US-		-					
		US-							
····		US-							
		US-				_			
		US-							
		US-					- 		
		US-							
		US-							
		US-							
		US-							
		US-							
		US-			, , ,	,	_		
EXAM	INER	SIGNATURE	•		DATE CONSIDER	ED			
*EXAN	ANE	R: Initial if reference considered, whe	ther or not o	citation is in	conformance with M	PEP 609 D	raw line through citation if not		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO						Application Number		ТВА			
TATEONRA ETON DICCI OCUDE						Int	ternational Filing Date	November 19, 2004			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Fir	rst Named Inventor	Mimi ADACHI, et al. TBA			
						Ar	rt Unit				
	((use a	is many s	sheets as necessary)		Ex	xaminer Name	Unassigned			
Sheet		2 of	4			At	Attorney Docket Number 64517.000003				
				F	OREIGN I	PAT	TENT DOCUMENTS				
FOREIGN PATENT											
ļ			· · · · ·	DOCUMENT	<u> </u>			Pages, Columns, Lines, Where	TRANSLATION		
*Examiner Initial	Cite No.		Country Code Number-Kind		Publication D MM-DD-YY		1 Marine Of Falence of	Relevant Passages or Relevant Figures Appear	YES NO		
	2.		wo	02/095026	11-28-200)2	Ikeda, et al.				
 											
·											
						-					
	—										
EXAMINER SIGNATURE					-	DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance and not considered. Include copy of this form with next com-								itation if	not in		

PTO/SB/08B (08/03) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for f	Form 1449/PTO	Applic	cation Number	ТВА			
TAIR	·An	A THOM DICCI OCUDE	Intern	national Filing Date	November 19, 2004			
	_	RMATION DISCLOSURE	First !	Named Inventor	Mimi ADACHI, et al.			
51 <i>P</i>		EMENT BY APPLICANT	Art U	nit	ТВА			
	(1	use as many sheets as necessary)	Exam	iner Name	Unassigned			
Sheet		3 of 4	Attori	ney Docket Number	64517.000003			
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS								
•Examiner Initials	Cite No.	Include name of the author (in CAPITAL item (book, magazine, journal, seria	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				ATION NO	
	3.	Tamamori-Adachi, et al., "Loss of skp2 Proliferative Capacity Induced by Cyclin	Tamamori-Adachi, et al., "Loss of skp2 Dependent Degradation of p27 Limits Cardiomyocyte Proliferative Capacity Induced by Cyclin D1NLS/CDK4," 26 th Annual Meeting of the Molecular Biology Society of Japan Program Abstract, November 25, 2003, pg.438, 01J-6.					
	4.		Tamamori-Adachi, et al., "Critical Role of Cyclin D1 Nuclear Import in Cardiomyocyte Proliferation," Circulation Research, Vol. 92, No. 1, pg. 1-8, 2003.					
	5.	Poolman, et al., "Altered Expression of Myocyte Hyperplasia in p27 ^{KIP1} Knockout 1999.						
	6.	Kim, et al., "Successful Inactivation of Preimplantation Embryos and Oocytes using Research Communications, Vol. 296, pg. 13						
	7.		Toyoshima, et al., "p27, a Novel Inhibitor of G1 Cyclin-Cdk Protein Kinase Activity, Is Related to p21," Cell, Vol. 78, No.1, pg. 67-74, July 15, 1994.					
	8.		Tsvetkov, et al., "p21 ^{Kip1} Ubiquitination and Degradation is Regulated by the SCF ^{Skp2} Complex Through Phosphorylated Thr187 in p27," Current Biology, Vol. 9, No.12, pg. 661-664, 1999.					
	9.	Pasumarthi, et al., "Cardiomyocyte Cell Cy 1054, 2002.	Pasumarthi, et al., "Cardiomyocyte Cell Cycle Regulation," Circulation Research, Vol. 90, pg. 1044-1054, 2002.					
	10.	Kirshenbaum, et al., "Adenovirus E1A Re Synthesis in Ventricular Myocytes, Via Al Journal of Biological Chemistry, Vol. 270,						
	11.	Kirshenbaum, et al., "Human E2F-1 React Represses Cardiac Gene Transcription," De						
	12.	Soonpaa, et al., "Cyclin D1 Overexpi Multinucleation in Transgenic Mice," J. Cli						
	13.	Toyoda, et al., "jumonji Downregulates Cardiac Cell Proliferation by Repressing cyclin DI Expression," Developmental Cell, Vol. 5, pg. 85-97, July 2003.						
EXAMI	NER	SIGNATURE	DATE CONSIDERED					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.								

PTO/SB/08B (08/03) (modified) EPARTMENT OF COMMERCE

U.S. Patent and	Trademark (Office: U.S.	DEPARTME!	NT OF	COMMERC
U.S. Fatelit and	I LAUCINAIN .	CHILDO, C.O.		,, ,,,	00111111

Substitute for form 1449/PTO			Application Number	ТВА				
			International Filing Date	ing Date November 19, 2004				
		RMATION DISCLOSURE	First Named Inventor	Mimi ADACHI, et al.	_			
STA	· -	EMENT BY APPLICANT	Art Unit	ТВА				
	(use as many sheets as necessary)	Examiner Name	Unassigned				
Sheet 4 of 4			Attorney Docket Number	64517.000003				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL item (book, magazine, journal, seria	LETTERS), title of the article (when app	TERS), title of the article (when appropriate), title of the posium, catalog, etc.), date, page(s), volume-issue				
	14.	Flink, et al., "Changes in E2F Complexes Containing Retinoblastoma Protein Family Members and Increased Cyclin-dependent Kinase Inhibitor Activities During Terminal Differentiation of Cardiomyocytes," J. Mol. Cell. Cardiol., Vol. 30, pg. 563-578, 1998.						
	15.	von Harsdorf, et al. "E2F-1 Overexpression in Cardiomyocytes Induces Downregulation of p21 ^{CIPI} and p27 ^{KIP1} and Release of Active Cyclin-Dependent Kinases in the Presence of Insulin-Like Growth Factor I," Circulation Research, Vol. 85, pg. 128-136, 1999.						
	16.	Carrano, et al., "SKP2 is Required for Ubiquitin-mediated Degradation of the CDK Inhibitor p27," Nature Cell Biology, Vol. 1, pg. 193-199, August 1999.						
	17.	Bornstein, et al., "Role of the SCF ^{Skp2} Ubiquitin Ligase in the Degradation of p21 ^{Cip1} in S Phase," The Journal of Biological Chemistry, Vol. 278, No. 28, pg. 25752-25757, July 11, 2003.						
	18.	Kamura, et al., "Degradation of p57 ^{Kip2} Mediated By SCF ^{Skp2} -dependent Ubiquitylation," Proc. Natl. Acad. Sci. USA, Vol. 100, No. 18, pg. 10231-10236, September 2, 2003.						
		-						
EXAMINER SIGNATURE DATE CONSIDERED								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								